While the role of contact tracing in the containment of the COVID-19 epidemic remains important until vaccines are widely available, literature on objectively measurable indicators for the effectiveness of contact tracing is scarce. We suggest the diagnostic serial interval, the time between the diagnosis of the infector and infectee, as a new indicator for the effectiveness of contact tracing. Using an agent-based simulation model, we demonstrate how the diagnostic serial interval correlates with the course of the epidemic. We consider four scenarios of how diagnosis and subsequent isolation are triggered: 1. never, 2. by symptoms, 3. by symptoms and loose contact tracing, 4. by symptoms and tight contact tracing. We further refine scenarios 3 and 4 with different lengths of target diagnostic serial intervals. Scenarios 1 and 2 did not yield a notable difference. In scenarios 3 and 4, however, contact tracing led to a decrease of the height of the epidemic as well as the cumulative proportion of infected agents. Generally, the shorter the diagnostic serial interval was, the smaller the peak of the epidemic became, and the more proportion of the population remained susceptible at the end of the epidemic. A short target diagnosis interval is critical for contact tracing to be effective in the epidemic control. The diagnosis interval can be used to assess and guide the contact tracing strategy.
Background: Age‐associated skin frailty affects hundreds of millions of adults globally. However, a validated and reliable scale to visually quantitate skin frailty is lacking, posing a barrier to clinical care and research. Objectives: To develop a validated and reliable visual scale for skin frailty and assess its association with demographic and clinical factors. Methods: Stanford Human Subjects Panel approval and informed consent were obtained prior to all procedures. Skin frailty parameters were identified on a literature review and assessed by two expert board‐certified dermatologists to generate content validity indices (CVIs). Skin frailty parameters on 219 digital photographs of the upper extremity in outpatient adult volunteers (age 18–89 years) were assessed, with reliability calculated by Kendall's coefficient or Gwet's AC2. A Skin Frailty Score (SFS) was developed using parameters with excellent, good, or moderate reliability. SFS was interrogated for the association with demographic/clinical factors. To improve SFS usability, factor analysis was performed to reduce the number of parameters, while retaining reliability and clinical relevance. Results: Nine parameters demonstrated CVI > 0.80. Strong intra‐rater reliability was observed for these 9 parameters (Kendall's coefficient or Gwet's AC2 > 0.80). Strong inter‐rater reliability was observed for 8/9 parameters (Kendall's coefficient and Gwet's AC2 > 0.80); one showed good inter‐rater reliability (Kendall's coefficient = 0.67). This 9‐parameter SFS demonstrated good intra‐rater reliability (intra‐class correlation coefficient = 0.85) and moderate inter‐rater reliability (intra‐class correlation coefficient = 0.69). By multivariate analysis, higher SFS was associated with age, female sex, and non‐melanoma skin cancer (all p < 0.01). To improve SFS usability, factor analysis enabled parameter reduction to 6, while maintaining moderate inter‐rater and good intra‐rater reliability (intra‐class correlation coefficient = 0.62 and 0.77, respectively) and clinical relevance. Conclusions: SFS is a novel, validated, and reliable visual scoring scale of skin frailty of the upper extremity that could be incorporated into clinical and research settings.